A novel approach to intra-individual performance variability in ADHD

• Published in: European child & adolescent psychiatry Vol. 30; no. 5; pp. 733 - 745
• Main Authors: Bluschke, Annet, Zink, Nicolas, Mückschel, Moritz, Roessner, Veit, Beste, Christian
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2021; Springer Nature B.V
• Subjects: Attention deficit hyperactivity disorder; Child & adolescent psychiatry; Child and Adolescent Psychiatry; Clinical medicine; Cognition & reasoning; Cognitive ability; Dopamine receptors; Drug therapy; Drugs; Hyperactivity; Medicine; Medicine & Public Health; Methylphenidate; Neurosciences; Noise; Original Contribution; Patients; Psychiatry; Standard deviation; Treatment methods; Variability; Attention deficit hyperactivity disorder; Methylphenidate; Intra-individual variability
• ISSN: 1018-8827; 1435-165X; 1435-165X
• DOI: 10.1007/s00787-020-01555-y

Patients with attention deficit/(hyperactivity) disorder (AD(H)D) show increased intra-individual variability (IIV) in behavioral performance. This likely reflects dopaminergic deficiencies. However, the precise performance profile across time and the pattern of fluctuations within it have not yet been considered, partly due to insufficient methods. Yet, such an analysis may yield important theory-based implications for clinical practice. Thus, in a case–control cross-sectional study, we introduce a new method to investigate performance fluctuations in patients with ADD ( n  = 76) and ADHD ( n  = 67) compared to healthy controls ( n  = 45) in a time estimation task. In addition, we also evaluate the effects of methylphenidate (MPH) treatment on this performance pattern in 29 patients with AD(H)D. Trial-by-trial differences in performance between healthy controls and patients with AD(H)D do not persist continuously over longer time periods. Periods during which no differences in performance between healthy controls and patients occur alternate with periods in which such differences are present. AD(H)D subtype and surprisingly also medication status does not affect this pattern. The presented findings likely reflect (phasic) deficiencies of the dopaminergic system in patients with AD(H)D which are not sufficiently ameliorated by first-line pharmacological treatment. The presented findings carry important clinical and scientific implications.